XenoPort Mails Letter to Stockholders Highlighting ISS’s Recommendation That XenoPort Stockholders Vote “FOR ALL” of

  XenoPort Mails Letter to Stockholders Highlighting ISS’s Recommendation That   XenoPort Stockholders Vote “FOR ALL” of XenoPort’s Director Nominees on the   WHITE Card  Business Wire  SANTA CLARA, Calif. -- June 3, 2014  XenoPort, Inc. (Nasdaq: XNPT) today announced that it is mailing a letter to stockholders in connection with the Company's upcoming Annual Meeting, which will be held onJune 11, 2014. The letter reviews the May 29, 2014 report issued by Institutional Shareholder Services (ISS), the leading independent proxy advisory firm, recommending that XenoPort stockholders vote on the WHITE proxy card “FOR ALL”  of XenoPort’s director nominees. On June 2, 2014, a second independent proxy advisory firm, Egan-Jones Proxy Services, also recommended that XenoPort stockholders vote “FOR ALL” of XenoPort’s director nominees on the WHITE proxy card.  Highlights of the letter include:    *ISS has recommended that XenoPort stockholders vote on the WHITE proxy     card “FOR ALL”  of XenoPort’s director nominees: Ronald W. Barrett,     Ph.D.,Jeryl L. HillemanandWendell Wierenga, Ph.D.;   *In supporting XenoPort's entire slate of director nominees, ISS     recommended that stockholders "do not vote" on the gold proxy card or for     any of the three nominees proposed by Clinton Relational Opportunity     Master Fund, L.P. and its affiliates (Clinton);   *In its May 29, 2014 report, ISS recognized the commercialization strategy     that XenoPort’s Board of Directors and leadership are executing for     HORIZANT^®(gabapentin enacarbil) Extended-Release Tablets;   *ISS also recognized the stepsXenoPortis taking to develop XP23829, a     potential treatment for psoriasis and/or relapsing forms of multiple     sclerosis (MS);   *In addition, ISS recommended XenoPort stockholders vote "FOR" the approval     of the XenoPort, Inc. 2014 Equity Incentive Plan, vote "FOR" the approval,     on an advisory basis, of the compensation of XenoPort's named executive     officers, and vote "FOR" the ratification of the selection by the audit     committee of the Board of Directors of Ernst & Young LLP as XenoPort's     independent registered public accounting firm for the fiscal year ending     December 31, 2014;   *XenoPort believes Clinton’s agenda would put XenoPort stockholders’     investment at risk; and   *The only way to vote for the XenoPort director nominees is to vote the     WHITE card.  The full text of the letter follows:   ISS, THE LEADING PROXY ADVISORY FIRM, RECOMMENDS XENOPORT STOCKHOLDERS VOTE                    FOR ALL OF XENOPORT’S DIRECTOR NOMINEES  June 2, 2014  Dear Fellow XenoPort Stockholder:  We are writing to inform you about an important development regarding XenoPort’s upcoming Annual Meeting on June 11, 2014.  The leading independent proxy advisory firm, Institutional Shareholder Services (ISS), has recommended that XenoPort stockholders vote on the WHITE proxy card “FOR ALL” of XenoPort’s director nominees: Ronald W. Barrett, Ph.D.,Jeryl L. HillemanandWendell Wierenga, Ph.D. ISS recommends that stockholders "do not vote" on the gold proxy card or for any of the three nominees proposed by Clinton Relational Opportunity Master Fund, L.P. and its affiliates (Clinton).  ISS issues proxy research and vote recommendations on approximately 39,000 companies in 115 countries each year.* ISS’s clients, who include institutional investors, pension funds and money managers, rely on ISS’s expertise, analysis and recommendations in making their voting decisions. The XenoPort Board of Directors appreciates that ISS is recommending that stockholders vote “FOR ALL” of XenoPort's director nominees.  In supporting XenoPort's entire slate of director nominees and recommending that stockholders "do not vote" for any of the three nominees proposed by Clinton, ISS stated in its May 29, 2014 report that “The dissident has not made a compelling case for the need for change at the board level.”**                          HIGHLIGHTS FROM THE ISS REPORT  ISS recognized the commercialization strategy that your Board of Directors and leadership are executing for HORIZANT^®(gabapentin enacarbil) Extended-Release Tablets. ISS stated:    *"the company's strategy to measure the uptake on a marketing program which     truly promoted the product appears justified. Moreover, the company's     decision to leverage$40 millionand 50 metric tons of active ingredient     acquired as part of settlement, implement state-of-the-art promotional     tools, personally promote and focus marketing efforts in 40 territories,     appears to be gaining traction. Using just 40 sales reps - compared to     GSK's 300 reps - that called on 10% of the potential market the company     has achieved the following results: a 24% increase in national prescribed     tablets, a 64% increase in XP territories prescribed tablets, and a 630%     increase in tablets prescribed per sales rep."   *"the board's reasons for terminating the licensing agreement with GSK,     reacquiring the rights to Horizant, and re-launching the drug in a     measured manner, to verify its potential appear justified by the early     results of that re-launch. Given the company is less than a year into the     re-launch, it appears too early to conclude a value maximizing decision     would not include the steps being currently undertaken at the company."   *"management's contention that ‘now may be the worst time to abandon     Horizant commercialization' - given that the heavy lifting of the initial     investment in the commercial operation has been completed, the investments     in marketing initiatives and programs are largely committed, and the     positive trajectory of actual sales will likely enhance the value of a     potential partnership or future divestiture of Horizant - appears to have     merit. So too do the facts that Horizant could generate meaningful revenue     to fund further XP23829 development, and that diverting funding from     Horizant to XP23829 will not accelerate XP829's development."  ISS also recognized the stepsXenoPortis taking to develop XP23829, a potential treatment for psoriasis and/or relapsing forms of multiple sclerosis (MS):    *"we find no evidence to support the dissident claim that XP829's     development is being neglected, capital starved, or that company's efforts     to maximize the value of Horizant have come at the expense of the     development of XP829. To the contrary, the strategy management has chosen     to move forward in psoriasis appears the quickest pathway towards value     creation for this asset and is echoed in analyst comments."  ISS also recommends XenoPort stockholders vote “FOR” the approval of XenoPort, Inc. 2014 Equity Incentive Plan, vote “FOR” the approval, on an advisory basis, the compensation of XenoPort’s named executive officers, and vote “FOR” the ratification of the selection by the audit committee of the Board of Directors of Ernst & Young LLP as XenoPort’s independent registered public accounting firm for the fiscal year ending December 31, 2014.    WE BELIEVE CLINTON’S AGENDA WOULD PUT YOUR INVESTMENT IN XENOPORT AT RISK  ISS’s recommendation further reinforces our belief that XenoPort has the right Board, the right leadership, and the right strategy to realize the full potential of XenoPort's assets and enhance stockholder value. In contrast, Clinton is pushing an agenda that we believe is short-term and puts at risk the opportunity for long-term value creation. Keep in mind: Clinton reportedly holds only 1.6% of XenoPort's common stock and began buying and selling XenoPort's shares just last year.  As ISS observed, XenoPort’s targeted commercialization strategy is building value in HORIZANT. Results of XenoPort's promotional efforts in just the first three full quarters since we re-acquired HORIZANT's rights demonstrate that our confidence in HORIZANT’s potential is justified. Initial investments in HORIZANT's commercial infrastructure are complete, and marketing budgets are largely committed. Now is the worst time to abandon commercialization as Clinton has suggested, particularly given the upward sales trends we are achieving.  As ISS recognized, XenoPort is taking appropriate steps to develop XP23829. Contrary to Clinton’s assertions, drug development is a step-wise and regulated process that requires much more than an ability to write a check. We have been fully investing in XP23829 and executing a thoughtful development plan that is appropriate for its stage of development.  All three of XenoPort’s director nominees, collectively and individually, bring expertise and skills critical to XenoPort’s success.            PROTECT YOUR INVESTMENT - VOTE THEWHITEPROXY CARD TODAY  Your Board is committed to realizing the full potential of XenoPort's assets and acting in the best interests of allXenoPortstockholders. We are making meaningful progress commercializing HORIZANT and are committed to optimizing the value of XP23829.  To follow the ISS recommendation on the election and XenoPort’s proposals, and protect your investment, vote the enclosedWHITEproxy card today "FOR ALL" of XenoPort's nominees:Ronald W. Barrett, Ph.D.,Jeryl L. HillemanandWendell Wierenga, Ph.D. and “FOR” the approval of XenoPort, Inc. 2014 Equity Incentive Plan, vote “FOR” the approval, on an advisory basis, the compensation of XenoPort’s named executive officers, and vote “FOR” the ratification of the selection by the audit committee of the Board of Directors of Ernst & Young LLP as XenoPort’s independent registered public accounting firm for the fiscal year ending December 31, 2014. Your Board also urges you to vote "FOR" Proposals 9 through 14 and "AGAINST" Clinton Proposals 5 through 8.   THE ONLY WAY TO VOTE FOR THE XENOPORT DIRECTOR NOMINEES IS TO VOTE THE WHITE                                      CARD  On behalf of your Board of Directors and management team, we thank you for your continued support.  Sincerely,  /s/ Ronald W. Barrett     /s/ John G. Freund Ronald W. Barrett, Ph.D.   John G. Freund, M.D. Chief Executive Officer    Lead Independent Director  * Source: ISS website ** Permission to use quotes was neither sought nor obtained  Forward-Looking Statements  This communication contains “forward-looking” statements, including, without limitation, all statements related to the potential value of XenoPort’s assets and XenoPort’s ability to achieve its goal of enhancing stockholder value through the execution of its strategic plan, including all statements related to the commercial, revenue and value opportunity for HORIZANT and the suitability of XP23829 as a potential treatment for psoriasis or relapsing forms of MS; XenoPort’s ability to build value in HORIZANT through, and the potential of, its targeted commercialization strategy; XenoPort’s current strategy for advancing the XP23829 clinical development program; potential partnering efforts for HORIZANT; and other statements that are not historical facts. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “believe,” “could,” “may,” “potential,” “will,” “would” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon XenoPort’s current expectations. Forward-looking statements involve risks and uncertainties. XenoPort’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation: risks related to XenoPort’s lack of commercialization experience and its ability to successfully market and sell HORIZANT, including XenoPort’s ability to maintain sales, marketing, distribution, supply chain and other sufficient capabilities to sell HORIZANT; XenoPort’s dependence on the success of its strategies for HORIZANT commercialization, promotion and distribution, as well as its ability to successfully execute on these activities and to comply with applicable laws, regulations and regulatory requirements; the competitive environment for and the degree of market acceptance of HORIZANT; obtaining appropriate pricing and reimbursement for HORIZANT in an increasingly challenging environment; the difficulty and uncertainty of pharmaceutical product development and the uncertain results and timing of clinical trials and other studies, including the risk that success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful; XenoPort’s ability to successfully advance XP23829 development and to conduct or initiate clinical trials in the anticipated timeframes, or at all; the uncertainty of the FDA’s review process and other regulatory requirements, including the risk that FDA action, including with respect to the investigational new drug application for XP23829, would delay or prevent the initiation of future clinical trials of XP23829; XenoPort’s need for and the availability of resources to develop XP23829 and to support XenoPort’s operations; XenoPort’s dependence on collaborative partners; the uncertain therapeutic and commercial value of HORIZANT and XP23829; as well as risks related to future opportunities and plans, including the uncertainty of future operating results. These and other risk factors are discussed under the heading “Risk Factors” in XenoPort’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2014, filed with the Securities and Exchange Commission on May 9, 2014. XenoPort expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.       If you have any questions, require assistance with voting your WHITE  proxy card or need additional copies of the proxy materials, please contact:                             MACKENZIE PARTNERS, INC.                                105 Madison Avenue                               New York, NY 10016                           proxy@mackenziepartners.com                          (212) 929-5500 (Call Collect)                                       Or                            TOLL-FREE (800) 322-2885  Important Additional Information and Where to Find It  XenoPort, Inc., its directors and certain of its executive officers may be deemed to be participants in the solicitation of proxies from stockholders in connection with XenoPort’s 2014 Annual Meeting of Stockholders. XenoPort has filed with the SEC and provided to its stockholders a definitive proxy statement and a WHITE proxy card in connection with such solicitation. XENOPORT STOCKHOLDERS ARE STRONGLY ENCOURAGED TO READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS AND SUPPLEMENTS) AND THE ACCOMPANYING WHITE PROXY CARD, AND ANY OTHER RELEVANT DOCUMENTS WHEN THEY BECOME AVAILABLE, BECAUSE THEY CONTAIN IMPORTANT INFORMATION.  Information regarding the names of XenoPort’s directors and executive officers and their respective interests in XenoPort by security holdings or otherwise is set forth in XenoPort’s definitive proxy statement for the 2014 Annual Meeting of Stockholders, filed with the SEC on April 22, 2014, including Appendix B thereto.  The definitive proxy statement (and amendments or supplements thereto) and the accompanying WHITE proxy card, and any other relevant documents and other material filed by XenoPort with the SEC, are or will be available for no charge at the SEC’s website at www.sec.gov and at XenoPort’s investor relations website at http://investor.xenoport.com/index.cfm. Copies may also be obtained free of charge by contacting XenoPort Investor Relations by mail at 3410 Central Expressway, Santa Clara, California 95051 or by telephone at (408) 616-7200.  About XenoPort  XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. XenoPort is currently commercializing HORIZANT in the United States and developing its novel fumaric acid ester product candidate, XP23829, as a potential treatment for patients with moderate-to-severe chronic plaque type psoriasis and/or relapsing forms of multiple sclerosis. REGNITE^® (gabapentin enacarbil) Extended-Release Tablets is being marketed in Japan by Astellas Pharma Inc. XenoPort's pipeline of product candidates also includes a potential treatment for patients with Parkinson's disease.  To learn more about XenoPort, please visit the website at www.XenoPort.com.  XNPT2G  Contact:  XenoPort, Inc. Jackie Cossmon, 408-616-7220 ir@XenoPort.com  
Press spacebar to pause and continue. Press esc to stop.